DEVELOPMENT OF THE MEBO TEST PROGRAM
For the past three years, since MEBO Research was just a distant dream beyond the horizon, the main driving force that propelled us to pursue this dream was the thought that somewhere in this world, there are sufferers who don’t have any recourse to have access to a test that would help them understand about their body odor condition or a treatment possibilities to cure it, or at least to control it.
In the long run, the MEBO Test Program aims to develop a more complete repertoire of varied body odor related diagnostic tests as well as research projects, under the guidance, direction, and supervision of Eliapharma and MEBO’s Scientific Advisors, in an effort to better understand the multiple causes of body odor conditions and their respective appropriate treatment. We are very fortunate to have the support and counsel of these, our experts, who have always been available and happy to help.
ABOUT ELIAPHARMA SERVICES INC
Eliapharma Services Inc. is a Contract Research Organization (CRO) located in Laval, Quebec, Canada.
Eliapharma Services Inc. has been in business for four successful years providing Analytical, Bio-analytical, Preclinical and Clinical Services for Biotechs, University Research Centers, Institutes, Pharmaceutical Companies, Generic Companies and Hospitals.
When will testing begin?
In order to be involved in the import and export of human specimens (urine or blood), Eliapharma has applied for an Import/Export Permit from the Canadian Authorities. We have been advised that the test kits cannot be mailed out to the 28 people currently on the waitlist to test until this permit has been issued, and the authorities tell us that it should be by December 2nd.
- The Human Pathogens and Toxins Act (HPTA) establishes legal prohibitions and authorities to govern human pathogens and toxins in Canada. It is designed to protect the health and safety of the public against the risks posed by human pathogens and toxins, while allowing science and research to progress.>
This laboratory has been classified as a Containment Level 2 laboratory by The Office of Laboratory Security, which outlines Operational Practices under the Public Health Agency of Canada. This Classification is valid for one year, and is described as follows:
- Containment Level 2 (CL2) See Organism Lists
This level applies to the laboratory handling agents requiring containment level 2. The primary exposure hazards associated with organisms requiring CL2 are through the ingestion, inoculation, and mucous membrane route. Agents requiring CL2 facilities are not generally transmitted by the airborne route, but care must be taken to avoid the generation of aerosols (aerosols can settle on benchtops and become an ingestion hazard by contamination of the hands) or splashes. Primary containment devices such as biological safety cabinets and centrifuges with sealed rotors or safety cups are to be used, as well as personal protective equipment (gloves, laboratory coats, protective eyewear). Environmental contamination must also be minimized by the use of hand washing sinks and decontamination facilities (autoclaves).
María de la Torre President and Executive Director
Related Posts:
MEBO and Eliapharma TMAU Testing and future research goals
MEBO and Eliapharma TMAU Testing Update 4
INTERNATIONAL TMAU TESTING UPDATE 2
INTERNATIONAL TMAU TESTING UPDATE
More about TMAU testing through MEBO Research
TMAU Test with Eliapharma through MEBO Research
International TMAU testing in Canada : Special Group Rates
0 comments: